Gene List


Guardant360 CDx is indicated to provide tumor mutation profiling for advanced cancer patients with any solid malignant neoplasm.
Guardant360 CDx report contains both professional services, which includes 74 genes, in addition to the FDA-approved report, which includes 55 genes.

Point Mutations (SNVs) and Deletion Variants (Indels)
(74 Genes)

AKT1 ALK APC AR ARAF ARID1A ATM BRAF BRCA1 BRCA2 CCND1 CCND2 CCNE1 CDH1 CDK4 CDK6 CDK12 CDKN2A CTNNB1 DDR2 EGFR ERBB2 ESR1 EZH2 FBXW7 FGFR1 FGFR2 FGFR3 GATA3 GNA11 GNAQ GNAS HNF1A HRAS IDH1 IDH2 JAK2 JAK3 KIT KRAS MAP2K1 MAP2K2 MAPK1 MAPK3 MET MLH1 MPL MTOR MYC NF1 NFE2L2 NOTCH1 NPM1 NRAS NTRK1 NTRK3 PDGFRA PIK3CA PTEN PTPN11 RAF1 RB1 RET RHEB RHOA RIT1 ROS1 SMAD4 SMO STK11 TERT^ TP53 TSC1 VHL

Amplifications
(18 Genes)

AR BRAF CCND1 CCND2 CCNE1 CDK4 CDK6 EGFR ERBB2 FGFR1 FGFR2 KIT KRAS MET MYC PDGFRA PIK3CA RAF1

Fusions
(6 Genes)

ALK FGFR2 FGFR3 NTRK1 RET ROS1

Critical or all exons* completely sequenced and all four major classes of alterations

NSCLC guideline-recommended genes shown in bold / *Exons selected to maximize detection of known somatic mutations / ^ Includes TERT promoter region